Milrinon Tillomed (Milrinone)

Milrinone, the active ingredient in Milrinon Tillomed, is a phosphodiesterase 3 inhibitor presented as an injectable solution for intravenous use. It improves cardiac output in acute decompensated heart failure and cardiogenic shock in hospitalized patients.

GNH USA supplies Milrinon Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive care units worldwide.

Milrinone is a phosphodiesterase‑3 inhibitor used in the management of severe cardiac dysfunction.

Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. Cardiogenic shock: provides inotropic support to maintain systemic perfusion. Post‑cardiac surgery low‑output syndrome: supports hemodynamics during recovery.

Milrinone may cause a range of adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Hypotension: reduced blood pressure, especially with rapid infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and redness of skin. - Tachycardia: increased heart rate. - Arrhythmias: premature beats or mild rhythm changes.

Serious or Rare Side Effects: - Severe arrhythmias: ventricular tachycardia or fibrillation. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Thrombocytopenia: significant drop in platelet count. - Severe hypotension: dangerous drop in blood pressure requiring intervention. - Anaphylaxis: rare allergic reaction with respiratory distress. - Hepatotoxicity: elevated liver enzymes indicating liver injury.

Milrinone requires careful monitoring and specific precautions before and during administration.

Blood pressure monitoring: observe for hypotension and adjust infusion rate. Cardiac rhythm surveillance: continuous ECG to detect arrhythmias. Renal function assessment: dose may need adjustment in renal impairment. Avoid in severe aortic stenosis: risk of excessive afterload reduction. Hypersensitivity screening: discontinue if allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Milrinone can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Other inotropes (e.g., dopamine): increased risk of arrhythmias. - Strong CYP3A4 inhibitors: may raise plasma milrinone levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt inotropic response. - Loop diuretics: additive hypotensive effect. - Anticoagulants: monitor for bleeding risk. - Digoxin: heightened arrhythmia potential. - ACE inhibitors: monitor blood pressure and renal function.